Table 2.
Summary of Medication Adherence and Tolerability
| All (n=62) | Female (n=23) | Male (n=39) | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Buspirone (n=35) | Placebo (n=27) | Total (n=62) | Buspirone (n=11) | Placebo (n=12) | Total (n=23) | Buspirone (n=24) | Placebo (n=15) | Total (n=39) | |
| Medication Adherence | |||||||||
| % Buspirone/Placebo pills taken: | |||||||||
| Self-report: mean (SD) a | 88.7% (21.6%) | 91.2% (17.0%) | 89.8% (19.7%) | 78.2% (32.5%) | 96.2% (4.5%) | 87.6% (24.0%) | 93.5% (12.5%) | 87.2% (22.0%) | 91.1% (16.8%) |
| Pill count: mean (SD)b | 94.4% (9.6%) | 95.8% (5.2%) | 95.0% (8.0%) | 92.2% (12.6%) | 97.1% (3.0%) | 94.7% (9.1%) | 95.5% (8.0%) | 94.8% (6.4%) | 95.2% (7.3%) |
| % Bottle openings: mean (SD) | 84.5% (22.0%) | 84.4% (20.5%) | 84.5% (21.2%) | 76.2% (31.1%) | 92.0% (7.9%) | 84.5% (23.1%) | 88.3% (15.6%) | 78.4% (25.4%) | 84.5% (20.2%) |
| % Urine samples positive for 1-PP: mean (SD) | 81.5% (25.4%) | -- | -- | 82.4% (27.3%) | -- | -- | 81.0% (25.1%) | -- | -- |
| Medication Tolerability | |||||||||
| Tolerability of maximum Buspirone/Placebo dose: | |||||||||
| Reached maximum: n (%) | 35 (100.0%) | 27 (100.0%) | 62 (100.0%) | 11 (100.0%) | 12 (100.0%) | 23 (100.0%) | 24 (100.0%) | 15 (100.0%) | 39 (100.0%) |
| Sustained dose at maximum: n (%) | 31 (88.6%) | 24 (88.9%) | 55 (88.7%) | 10 (90.9%) | 11 (91.7%) | 21 (91.3%) | 21 (87.5%) | 13 (86.7%) | 34 (87.2%) |
a
Self-reported adherence was calculated as (total mgs. taken)/(total mgs. prescribed) expressed as a percent;
b
Pill count adherence was calculated: (pills dispensed − pills returned − pills reported lost)/(pills dispensed − expected pills returned) expressed as a percent. In cases where participants failed to return their medication bottles, those bottles were excluded from the analysis.